Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts

Leukemia

Volumn 16, Issue 10, 2002, Pages 2062-2071

  Baumgartner, B ^a   Weber, M ^a   Quirling, M ^a   Fischer, C ^a   Page, S ^a   Adam, M ^c   Von Schilling, C ^b   Waterhouse, C ^d   Schmid, C ^c   Neumeier, D ^a   Brand, K ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NONE   (Germany)

Author keywords

AML; IKK complex; Leukemia; NF B

Indexed keywords

CHUK PROTEIN, HUMAN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROTEIN SERINE THREONINE KINASE; TUMOR NECROSIS FACTOR ALPHA; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CELL NUCLEUS; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; HUMAN; MALE; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; ACUTE GRANULOCYTIC LEUKEMIA; BIOASSAY; BLAST CELL; BONE MARROW CELL; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKEMIA CELL; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL NUCLEUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; I-KAPPA B KINASE; LEUKEMIA, MYELOID; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036771841     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402641     Document Type: Article

References (46)

1. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996; 87: 13-20.
2. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995; 80: 529-532.
3. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-κB in atherogenesis. Exp Physiol 1997; 82: 297-304.
4. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470: M55-M62.
5. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dörken B. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-4347.
6. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
7. Whiteside ST, Israel A. I kappa B proteins: structure, function and regulation. Semin Cancer Biol 1997; 8: 75-82.
8. May MJ, Ghosh S. Rel/NF-kappaB and I kappa B proteins: an overview. Semin Cancer Biol 1997; 8: 63-73.
9. Wulczyn FG, Krappmann D, Scheidereit C. The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation. J Mol Med 1996; 74: 749-769.
10. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
11. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, Kaltschmidt C, Neumann FJ, Mackman N, Baeuerle PA, Walli AK, Neumeier D. Dysregulation of monocytic nuclear factor-κB by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17: 1901-1909.
12. Page S, Fischer C, Baumgartner B, Haas M, Kreusel U, Loidl G, Hayn M, Ziegler-Heitbrock HWL, Neumeier D, Brand K. 4-Hydroxynonenal prevents NF-κB activation and TNF expression by inhibiting IκB phosphorylation and subsequent proteolysis. J Biol Chem 1999; 274: 11611-11618.
13. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated transcriptional activation of human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor κB binding sites. J Exp Med 1991; 174: 1517-1526.
14. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663.
15. Israel A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000; 10: 129-133.
16. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IkappaB kinase-beta: NF-kappaB activation and complex formation witk IkappaB kinase-alpha and NIK. Science 1997; 278: 866-869.
17. Fischer C, Page S, Weber M, Eisele T, Neumeier D, Brand K. Different effects of LPS and TNF on monocytic IKK signalsome activation and IκB proteolysis. J Biol Chem 1999; 274: 24625-24632.
18. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953.
19. Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. Oncogene 1999; 18: 6948-6958.
20. Dokter WHA, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous expression of interleukin-1β and interleukin-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia 1995; 9: 425-432.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
22. McKenna RW. Multifaceted approach to the diagnosis and classification of acute leukemias. Clin Chem 2000; 46: 1252-1259.
23. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
24. Brand K, Mackman N, Curtiss LK. Interferon-γ inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 1993; 91: 2031-2039.
25. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000; 36: 151-169.
26. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 1999; 18: 6910-6924.
27. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dörken B, Ludwig W-D, Karawajew L. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity. Leukemia 2001; 15: 921-928.
28. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
29. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto, N. Constitutive activation of NF-kappa B in primary adult T-cell leukemia cells. Blood 1999; 93: 2360-2368.
30. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
31. Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113: 56-60.
32. Wood KM, Roff M, Hay RT. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene 1998; 16: 2131-2139.
33. Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET, Grant M, Connelly MA, Hambor JE, Marcu KB, Greene WC. Human T-cell leukemia virus type 1 Tax induction of NF-κB involves activation of the IκB kinase a (IKKα) and IKKβ cellular kinases. Mol Cell Biol 1998; 18: 5157-5165.
34. Devalaraja MN, Wang DZ, Ballard DW, Richmond A. Elevated constitutive IκB kinase activity and IκB-α phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-α transcription. Cancer Res 1999; 59: 1372-1377.
35. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE. Role of the IκB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 2000; 20: 5381-5391.
36. Greer JP, Baer MR, Kinney MC. Acute myelogenous leukemia. In: Lee G, Foerster J, Lukens J, Paraskevas F, Rodgers G (eds). Wintrobe's Clinical Hematology, 10th edn. Lippincott Williams & Wilkins: Philadelphia, 1998, pp 2272-2319.
37. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-176.
38. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer RD, Grinstein E, Greiner A, Scheidereit C, Dörken B. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969.
39. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 2000; 19: 1123-1131.
40. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dörken B. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-3134.
41. Baichwal VR, Baeuerle PA. Apoptosis: Activate NF-κB or die? Curr Biol 1997; 7: R94-R96.
42. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624-4631.
43. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti C, Del Vecchio L, Turco MC, Venuta S. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000; 7: 1234-1237.
44. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 2000; 289: 1550-1554.
45. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 1999; 94: 2844-2853.
46. Burnett AK, Eden OB. The treatment of acute leukemia. Lancet 1997; 349: 270-275.